Rain Oncology Inc.(NASDAQ:RAIN) 
Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p5...
Website: https://www.rainoncology.com
Founded: 2017
Full Time Employees: 63
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2023-08-01
P
O 1.30
H 1.35
L 1.25
C 1.27
V 284,175
10EMA 1.27
20EMA 1.27
60EMA 1.27
120EMA 1.27
250EMA 1.27